Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hipofen-mediated photodynamic therapy for cholangiocarcinoma
ChiCTR2100049107Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ibuprofen in cholangiocarcinoma (CCA) (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: objective remission rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
ibuprofen
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2100049107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049107.